Compare Glenmark Pharma with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs AUROBINDO PHARMA - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA AUROBINDO PHARMA GLENMARK PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 12.0 14.2 84.5% View Chart
P/BV x 1.7 3.1 55.6% View Chart
Dividend Yield % 0.6 0.4 139.1%  

Financials

 GLENMARK PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
AUROBINDO PHARMA
Mar-18
GLENMARK PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs712809 88.0%   
Low Rs484504 96.0%   
Sales per share (Unadj.) Rs349.6281.1 124.4%  
Earnings per share (Unadj.) Rs32.841.4 79.3%  
Cash flow per share (Unadj.) Rs44.350.9 87.1%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.30.4 87.9%  
Book value per share (Unadj.) Rs198.6199.4 99.6%  
Shares outstanding (eoy) m282.17585.88 48.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.3 73.2%   
Avg P/E ratio x18.215.9 114.8%  
P/CF ratio (eoy) x13.512.9 104.5%  
Price / Book Value ratio x3.03.3 91.4%  
Dividend payout %6.16.0 100.9%   
Avg Mkt Cap Rs m168,625384,630 43.8%   
No. of employees `00012.017.3 69.4%   
Total wages/salary Rs m20,56121,308 96.5%   
Avg. sales/employee Rs Th8,196.09,500.7 86.3%   
Avg. wages/employee Rs Th1,708.11,229.4 138.9%   
Avg. net profit/employee Rs Th768.51,397.9 55.0%   
INCOME DATA
Net Sales Rs m98,655164,666 59.9%  
Other income Rs m2,0811,020 204.1%   
Total revenues Rs m100,736165,686 60.8%   
Gross profit Rs m15,85837,718 42.0%  
Depreciation Rs m3,2595,580 58.4%   
Interest Rs m3,346777 430.5%   
Profit before tax Rs m11,33532,380 35.0%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,7568,183 45.9%   
Profit after tax Rs m9,25024,229 38.2%  
Gross profit margin %16.122.9 70.2%  
Effective tax rate %33.125.3 131.1%   
Net profit margin %9.414.7 63.7%  
BALANCE SHEET DATA
Current assets Rs m66,968121,878 54.9%   
Current liabilities Rs m40,21186,806 46.3%   
Net working cap to sales %27.121.3 127.3%  
Current ratio x1.71.4 118.6%  
Inventory Days Days83130 64.2%  
Debtors Days Days8168 118.8%  
Net fixed assets Rs m33,32281,037 41.1%   
Share capital Rs m282586 48.2%   
"Free" reserves Rs m55,770116,218 48.0%   
Net worth Rs m56,052116,804 48.0%   
Long term debt Rs m35,7384,512 792.1%   
Total assets Rs m132,888211,052 63.0%  
Interest coverage x4.442.7 10.3%   
Debt to equity ratio x0.60 1,650.5%  
Sales to assets ratio x0.70.8 95.2%   
Return on assets %9.511.8 80.0%  
Return on equity %16.520.7 79.6%  
Return on capital %17.827.4 65.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99880,727 78.0%   
Fx outflow Rs m22,85934,700 65.9%   
Net fx Rs m40,14046,027 87.2%   
CASH FLOW
From Operations Rs m13,24219,548 67.7%  
From Investments Rs m-6,990-19,570 35.7%  
From Financial Activity Rs m-7,3878,642 -85.5%  
Net Cashflow Rs m-2,9718,922 -33.3%  

Share Holding

Indian Promoters % 48.3 54.1 89.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 8.0 86.8%  
FIIs % 34.4 27.7 124.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.2 102.9%  
Shareholders   56,727 69,601 81.5%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT  ABBOTT INDIA  PLETHICO PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Rally; Sensex Zooms 1,250 Points(12:30 pm)

Share markets in India are presently trading on a strong note, cheering the government's move to cut corporate tax rates to boost economic growth.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)

Sep 20, 2019

Are investors overdoing their euphoria post the corporate tax cut bonanza?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 23, 2019 02:51 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS